FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2500481180> ?p ?o ?g. }

• W2500481180 abstract "The randomized, double-blind CANTATA-SU (CANagliflozin Treatment And Trial Analysis Sulfonyl Urea) clinical trial compared the use of canagliflozin (100 mg or 300 mg) and maximally tolerated glimepiride (6-8 mg) over 104 weeks as add-on therapy for patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Compared with glimepiride, canagliflozin use was associated with durable reductions in glycated hemoglobin (A1C), blood pressure (BP), and body weight. The aim of this post-hoc analysis of the CANTATA-SU trial was to assess the comparative efficacy of canagliflozin and glimepiride in the attainment of recently updated diabetes-related quality measures (QMs) for up to 104 weeks of treatment.This post-hoc analysis evaluated the proportions of patients achieving individual diabetes-related QMs using data from the randomized, double-blind, Phase 3 CANTATA-SU trial. Change in A1C from baseline, and proportions of the study population achieving QMs: A1C <7.0 %, <8.0 %, and >9.0 % were assessed. Secondary endpoints included change in BP from baseline, and the proportions of the study population achieving QMs related to BP and body weight.The proportions of patients in the canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride groups meeting criteria for all QMs were similar at baseline. At 52 and 104 weeks of treatment, canagliflozin 100 mg and canagliflozin 300 mg provided better or similar reductions in A1C from baseline and achievement of glycemic control QMs compared with glimepiride. At 52 and 104 weeks of treatment, the attainment of QMs related to reductions in body weight and BP all favored canagliflozin compared with glimepiride. Canagliflozin was associated with lower incidence of documented hypoglycemia and severe hypoglycemia compared with glimepiride.Using the recently adjusted and currently accepted diabetes-related QMs, this analysis observed superior glycemic control with canagliflozin compared with maximally tolerated glimepiride in patients with T2DM who were previously poorly controlled on metformin monotherapy. Compared with maximally tolerated glimepiride, canagliflozin resulted in better achievement of diabetes-related QMs related to weight loss and BP, and was associated with lower incidences of hypoglycemic events.Clinical trial registry name: CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride.NCT00968812 , registered August 28, 2009." @default.
• W2500481180 created "2016-08-23" @default.
• W2500481180 creator A5014048408 @default.
• W2500481180 creator A5026752543 @default.
• W2500481180 creator A5031542137 @default.
• W2500481180 creator A5068523311 @default.
• W2500481180 creator A5070289715 @default.
• W2500481180 date "2016-08-05" @default.
• W2500481180 modified "2023-10-07" @default.
• W2500481180 title "A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures" @default.
• W2500481180 cites W167074208 @default.
• W2500481180 cites W1924318177 @default.
• W2500481180 cites W1955935325 @default.
• W2500481180 cites W1957004156 @default.
• W2500481180 cites W1980847189 @default.
• W2500481180 cites W2008443217 @default.
• W2500481180 cites W2008687581 @default.
• W2500481180 cites W2016782248 @default.
• W2500481180 cites W2018192866 @default.
• W2500481180 cites W2023984564 @default.
• W2500481180 cites W2040580117 @default.
• W2500481180 cites W2047094893 @default.
• W2500481180 cites W2047553605 @default.
• W2500481180 cites W2052503411 @default.
• W2500481180 cites W2066042413 @default.
• W2500481180 cites W2072040765 @default.
• W2500481180 cites W2076599880 @default.
• W2500481180 cites W2084380924 @default.
• W2500481180 cites W2107288531 @default.
• W2500481180 cites W2111876001 @default.
• W2500481180 cites W2116974726 @default.
• W2500481180 cites W2126125759 @default.
• W2500481180 cites W2130570549 @default.
• W2500481180 cites W2135880911 @default.
• W2500481180 cites W2146264128 @default.
• W2500481180 cites W2153658404 @default.
• W2500481180 cites W2154525074 @default.
• W2500481180 cites W2159183792 @default.
• W2500481180 cites W2160088494 @default.
• W2500481180 cites W2166823746 @default.
• W2500481180 cites W2172193326 @default.
• W2500481180 cites W2179831365 @default.
• W2500481180 cites W2211492625 @default.
• W2500481180 cites W2301210108 @default.
• W2500481180 cites W4240794548 @default.
• W2500481180 cites W4247910510 @default.
• W2500481180 doi "https://doi.org/10.1186/s12913-016-1607-z" @default.
• W2500481180 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4974722" @default.
• W2500481180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27495291" @default.
• W2500481180 hasPublicationYear "2016" @default.
• W2500481180 type Work @default.
• W2500481180 sameAs 2500481180 @default.
• W2500481180 citedByCount "6" @default.
• W2500481180 countsByYear W25004811802017 @default.
• W2500481180 countsByYear W25004811802018 @default.
• W2500481180 countsByYear W25004811802019 @default.
• W2500481180 countsByYear W25004811802020 @default.
• W2500481180 countsByYear W25004811802021 @default.
• W2500481180 crossrefType "journal-article" @default.
• W2500481180 hasAuthorship W2500481180A5014048408 @default.
• W2500481180 hasAuthorship W2500481180A5026752543 @default.
• W2500481180 hasAuthorship W2500481180A5031542137 @default.
• W2500481180 hasAuthorship W2500481180A5068523311 @default.
• W2500481180 hasAuthorship W2500481180A5070289715 @default.
• W2500481180 hasBestOaLocation W25004811801 @default.
• W2500481180 hasConcept C126322002 @default.
• W2500481180 hasConcept C126894567 @default.
• W2500481180 hasConcept C134018914 @default.
• W2500481180 hasConcept C168563851 @default.
• W2500481180 hasConcept C2776307423 @default.
• W2500481180 hasConcept C2777180221 @default.
• W2500481180 hasConcept C2777451236 @default.
• W2500481180 hasConcept C2780323712 @default.
• W2500481180 hasConcept C2780473172 @default.
• W2500481180 hasConcept C2780668416 @default.
• W2500481180 hasConcept C2908647359 @default.
• W2500481180 hasConcept C555293320 @default.
• W2500481180 hasConcept C67761136 @default.
• W2500481180 hasConcept C71924100 @default.
• W2500481180 hasConcept C99454951 @default.
• W2500481180 hasConceptScore W2500481180C126322002 @default.
• W2500481180 hasConceptScore W2500481180C126894567 @default.
• W2500481180 hasConceptScore W2500481180C134018914 @default.
• W2500481180 hasConceptScore W2500481180C168563851 @default.
• W2500481180 hasConceptScore W2500481180C2776307423 @default.
• W2500481180 hasConceptScore W2500481180C2777180221 @default.
• W2500481180 hasConceptScore W2500481180C2777451236 @default.
• W2500481180 hasConceptScore W2500481180C2780323712 @default.
• W2500481180 hasConceptScore W2500481180C2780473172 @default.
• W2500481180 hasConceptScore W2500481180C2780668416 @default.
• W2500481180 hasConceptScore W2500481180C2908647359 @default.
• W2500481180 hasConceptScore W2500481180C555293320 @default.
• W2500481180 hasConceptScore W2500481180C67761136 @default.
• W2500481180 hasConceptScore W2500481180C71924100 @default.
• W2500481180 hasConceptScore W2500481180C99454951 @default.
• W2500481180 hasLocation W25004811801 @default.
• W2500481180 hasLocation W25004811802 @default.
• W2500481180 hasLocation W25004811803 @default.
• W2500481180 hasLocation W25004811804 @default.
• W2500481180 hasOpenAccess W2500481180 @default.

• next